NuCana

NCNA NASDAQ
12.20
+0.47
+4.01%
Closed 16:00 06/18 EDT
Open
12.29
Prev Close
11.73
High
12.63
Low
12.02
Volume
8.07K
Avg Vol (3M)
40.74K
52 Week High
30.10
52 Week Low
10.37
% Turnover
0.03%
Market Cap
388.10M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers NuCana NCNA stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.
MORE >

Recently

Name
Price
%Change